.Charles Baum, M.D., Ph.D., who managed Mirati Rehabs’ $ 5.8 billion sale to Bristol Myers Squibb in 2015, is taking the reins of young biotech Terremoto Biosciences.Baum’s “substantial expertise in drug development, and proven track record in advancing high-impact medicines, will certainly contribute,” outbound chief executive officer Peter Thompson, M.D., claimed in a July 25 release. Thompson is going to maintain his seat as board chairperson..Baum, an experienced physician-scientist, was the founder, president and also chief executive officer of oncology-focused Mirati. Prior to that, he assisted build cancer cells drugs at Pfizer and also Schering-Plough..
Charles Baum, M.D., Ph.D.(( Mirati)).Right now, Baum will definitely work as chief executive officer at Terremoto, a business developing small molecules to target disease-causing healthy proteins– like those located in cancerous growth cells– making use of covalent bonds. Existing treatments that utilize covalent bonds mainly target the amino acid cysteine. Nevertheless, of the 20 amino acids that compose proteins, cysteine is actually the least common.
Terremoto is actually instead targeting one of the important amino acids, amino acid lysine, which is discovered in nearly all proteins.Through targeting amino acid lysine and also various other amino acids, Terremoto wants to deal with recently undruggable health conditions as well as develop first-in-class medicines..The biotech, located in South San Francisco, increased $75 thousand in collection A backing in 2022. A little bit of more than a year later on, the biotech greater than multiplied that amount in a $175 million series B.